


**Amendments to the Claims:**

This listing of claims replaces all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A compound of Formula I



or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl or naphthyl;

A is selected from: ~~-CO<sub>2</sub>H, 1H-tetrazol-5-yl, PO<sub>3</sub>H<sub>2</sub>, PO<sub>2</sub>H<sub>2</sub>, SO<sub>3</sub>H, and -PO(R<sup>5</sup>)OH, wherein R<sup>5</sup> is selected from the group consisting of: C<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkyl, phenyl, C(O)-C<sub>1-3</sub>alkoxy and -CH(OH)-phenyl, said phenyl and phenyl portion of -CH(OH)-phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of: -hydroxyl, halo, -CO<sub>2</sub>H, C<sub>1-4</sub>alkyl, S(O)<sub>k</sub>C<sub>1-3</sub>alkyl, wherein k is 0, 1 or 2, C<sub>1-3</sub>alkoxy, C<sub>3-6</sub>cycloalkoxy, aryl and aralkoxy, the alkyl portions of said C<sub>1-4</sub>alkyl, S(O)<sub>k</sub>C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy and C<sub>3-6</sub>cycloalkoxy optionally substituted with 1-3 halo groups;~~

n is 2, 3 or 4;

each R<sup>1</sup> and R<sup>2</sup> is each independently selected from the group consisting of: hydrogen, halo, hydroxy, -CO<sub>2</sub>H, C<sub>1-6</sub>alkyl and phenyl, said C<sub>1-6</sub>alkyl and phenyl optionally substituted with 1-3 halo groups;

R<sup>3</sup> is selected from the group consisting of: hydrogen and C<sub>1-4</sub>alkyl, optionally substituted with 1-3 hydroxy or halo groups;

each R<sup>4</sup> is independently selected from the group consisting of: hydroxy, halo, -CO<sub>2</sub>H, C<sub>1-4</sub>alkyl, -S(O)<sub>k</sub>C<sub>1-3</sub>alkyl, wherein k is 0, 1 or 2, C<sub>1-3</sub>alkoxy, C<sub>3-6</sub> cycloalkoxy, aryl and aralkoxy, the alkyl portions of said C<sub>1-4</sub>alkyl, -S(O)<sub>k</sub>C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy and C<sub>3-6</sub> cycloalkoxy optionally substituted with 1-3 halo groups;


C is selected from the group consisting of:

- (1) ~~C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, (C=O)C<sub>1-6</sub>alkyl or CHOH-C<sub>1-6</sub>alkyl, said C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, (C=O)C<sub>1-6</sub>alkyl and CHOH-C<sub>1-6</sub>alkyl optionally substituted with phenyl, and~~
- (2) ~~phenyl or HET, wherein HET is thienyl each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy, said C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxyl, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C<sub>1-4</sub>alkyl, optionally substituted with 1-3 halo groups,~~

or C is not present;

~~when C is not present then B is selected from the group consisting of: phenyl, C<sub>5-16</sub>alkyl, C<sub>5-16</sub>alkenyl, C<sub>5-16</sub>alkynyl, CHOH-C<sub>4-15</sub>alkyl, CHOH-C<sub>4-15</sub>alkenyl, CHOH-C<sub>4-15</sub>alkynyl, C<sub>4-15</sub>alkoxy, O-C<sub>4-15</sub>alkenyl, O-C<sub>4-15</sub>alkynyl, C<sub>4-15</sub>alkylthio, S-C<sub>4-15</sub>alkenyl, S-C<sub>4-15</sub>alkynyl, CH<sub>2</sub>-C<sub>3-14</sub>alkoxy, CH<sub>2</sub>-O-C<sub>3-14</sub>alkenyl, CH<sub>2</sub>-O-C<sub>3-14</sub>alkynyl, (C=O)-C<sub>4-15</sub>alkyl, (C=O)-C<sub>4-15</sub>alkenyl, (C=O)-C<sub>4-15</sub>alkynyl, (C=O)-O-C<sub>3-14</sub>alkyl, (C=O)-O-C<sub>3-14</sub>alkenyl, (C=O)-O-C<sub>3-14</sub>alkynyl, (C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>3-14</sub>alkyl, (C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>3-14</sub>alkenyl, (C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>3-14</sub>alkynyl, N(R<sup>6</sup>)(R<sup>7</sup>)-(C=O)-C<sub>3-14</sub>alkyl, N(R<sup>6</sup>)(R<sup>7</sup>)-(C=O)-C<sub>3-14</sub>alkenyl and N(R<sup>6</sup>)(R<sup>7</sup>)-(C=O)-C<sub>3-14</sub>alkynyl,~~

~~when C is phenyl or HET then B is selected from the group consisting of: C<sub>1-6</sub>alkyl, C<sub>1-5</sub>alkoxy, -(C=O)-C<sub>1-5</sub>alkyl, -(C=O)-O-C<sub>1-4</sub>alkyl, -(C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>1-4</sub>alkyl, C<sub>1-3</sub>alkyl~~



~~, phenyl and HET, and~~

~~when C is C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkoxy, -(C=O)-C<sub>1-6</sub>alkyl or -CHOH-C<sub>1-6</sub>alkyl then B is phenyl; and~~

R<sup>6</sup> and R<sup>7</sup> are independently selected from the group consisting of: hydrogen, C<sub>1-9</sub>alkyl and -(CH<sub>2</sub>)<sub>p</sub>-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C<sub>1-3</sub>alkyl and C<sub>1-3</sub>alkoxy, each optionally substituted with 1-3 halo groups.

2. (canceled)

3. (original) The compound according to Claim 1 wherein n is 2.

4. (original) The compound according to Claim 1 wherein n is 3.

5. (original) The compound according to Claim 3 wherein each R<sup>1</sup> and R<sup>2</sup> is independently selected from the group consisting of: hydrogen, -CO<sub>2</sub>H, hydroxy, halo, C<sub>1-3</sub>alkyl and phenyl.


6 to 10. (canceled)

11. (original) The compound according to Claim 1 wherein R<sup>3</sup> is hydrogen or methyl.


12. (original) The compound according to Claim 1 wherein each R<sup>4</sup> is independently selected from the group consisting of: halo, hydroxy, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, phenyl, benzyloxy and cyclopropyloxy.

13 to 17. (canceled)

18. (original) The compound according to Claim 1 wherein **B-C** is




or



19. (original) The compound according to Claim 1 wherein Ar is phenyl and the group **-B-C** is attached to the phenyl ring at the 3- or 4-position.

20. (currently amended) A compound of Formula II



## II

or a pharmaceutically acceptable salt or hydrate thereof, wherein

the group **-B-C** is attached to the phenyl ring at the 3- or 4-position;

n is 2, 3 or 4;

each R<sup>1</sup> and R<sup>2</sup> is independently selected from the group consisting of: hydrogen, -CO<sub>2</sub>H, hydroxy, halo, C<sub>1-3</sub>alkyl and phenyl, said C<sub>1-3</sub>alkyl and phenyl optionally substituted with 1-3 halo group;

~~A is selected from the group consisting of: 1H-tetrazol-5-yl, PO<sub>2</sub>H<sub>2</sub>, PO<sub>3</sub>H<sub>2</sub>, -CO<sub>2</sub>H and PO(R<sup>5</sup>)OH, wherein R<sup>5</sup> is selected from the group consisting of: C<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkyl, C(O)-C<sub>1-2</sub>alkoxy and benzyl, wherein both the methyl and phenyl portions of said benzyl are optionally substituted with 1-3 halo or hydroxyl groups;~~

R<sup>3</sup> is hydrogen or methyl;

each R<sup>4</sup> is independently selected from the group consisting of: halo, hydroxy, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkylthio, phenyl, benzyloxy and cyclopropyloxy; and

~~**B-C** is selected from the group consisting of:~~

~~—— (1) — **B** is C<sub>8-10</sub>alkyl and **C** is not present.~~


~~—— (2) — **B** is C<sub>4-11</sub>alkoxy and **C** is not present.~~

~~—— (3) — **B** is phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy, and **C** is selected from the group consisting of: hydrogen, phenyl, C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkoxy, (C=O)-C<sub>1-6</sub>alkyl and -CHOH-C<sub>1-6</sub>alkyl, said C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkoxy, (C=O)-C<sub>1-6</sub>alkyl and -CHOH-C<sub>1-6</sub>alkyl optionally substituted with phenyl;~~


~~(4) B is CHOH-C<sub>6-10</sub>alkyl, C<sub>6-10</sub>alkylthio, CH<sub>2</sub>-C<sub>5-9</sub>alkoxy, (C=O)-C<sub>6-10</sub>alkyl, (C=O)-O-C<sub>5-9</sub>alkyl, (C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>5-9</sub>alkyl or N(R<sup>6</sup>)(R<sup>7</sup>)-(C=O)-C<sub>5-9</sub>alkyl, and C is not present.~~

~~(5) B is C<sub>1-6</sub>alkyl or C<sub>1-5</sub>alkoxy and C is phenyl.~~


~~(6) B-C is~~



or





21. (currently amended) A compound selected from the group consisting of:






Serial No.: 10/500,811  
Case No.: 21020P  
Page 8














Page 11






























































or a pharmaceutically acceptable salt of any of the foregoing compounds.

22. (withdrawn) A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

23 to 33. (canceled)

34. (withdrawn) A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

35. (canceled)